文献速递产科母胎医学

血清可溶性fms样酪氨酸激酶1/胎盘生长因子检测用于妊娠期高血压疾病住院患者常规临床评估的真实世界证据

Real-world evidence for the utility of serum soluble fms-like tyrosine kinase 1/placental growth factor test for routine clinical evaluation of hospitalized women with hypertensive disorders of pregnancy.
PubMed 文献 · Am J Obstet Gynecol · 2024-07-17

该前瞻性研究在2023年6月至2024年1月纳入65例妊娠23周至34周6天的妊娠期高血压疾病住院患者,将可溶性fms样酪氨酸激酶1/胎盘生长因子比值≥40用于风险分层。比值<40组2周内因妊娠期高血压疾病分娩率显著低于≥40组(5.6% vs 72.4%),发生重度子痫前期风险亦更低;低比值组妊娠延长且未增加母婴不良结局。

要点

  • 比值<40组2周内因妊娠期高血压疾病分娩率5.6%(2/36),比值≥40组72.4%(21/29)。
  • 比值<40组2周内重度子痫前期发生率5.6%(2/36),比值≥40组79.3%(23/29)。
  • 比值<40组母婴不良事件发生率8.3%(3/36),比值≥40组34.5%(10/29)。

核心结论

  • 将可溶性fms样酪氨酸激酶1/胎盘生长因子比值纳入临床实践可作为评估妊娠期高血压疾病患者进展为重度子痫前期及不良结局风险的可靠补充。
  • 低比值患者妊娠可能延长,从而改善新生儿结局且不伤害母亲。

研究设计与样本

  • 前瞻性研究,2023年6月至2024年1月纳入妊娠23周至34周6天的妊娠期高血压疾病住院患者65例。
  • 在将血清可溶性fms样酪氨酸激酶1/胎盘生长因子检测纳入常规临床实践后开展,检测结果在静脉穿刺后24小时内可供临床医生获取。
  • 医生在实施前接受基于生物标志物的合理使用和管理指南教育,但独立做出实用管理决策。

主要发现

  • 比值<40组2周内因妊娠期高血压疾病分娩率5.6%(2/36),比值≥40组72.4%(21/29),校正混杂因素后调整风险比7.52(95%CI 3.05-18.54,P<.001)。
  • 比值<40组2周内重度子痫前期发生率5.6%(2/36),比值≥40组79.3%(23/29),P<.001;阳性预测值79%(95%CI 0.65-0.94),阴性预测值0.94(95%CI 0.87-1.00)。
  • 2周内发生重度子痫前期的阳性似然比和阴性似然比分别为6.13和0.09。
  • 比值<40组母婴不良事件发生率8.3%(3/36),比值≥40组34.5%(10/29),P=.01。
  • 36例低比值患者中22例就诊时有类似子痫前期的可疑临床或实验室标准,基于生物标志物期待管理,2周时无一例发生重度子痫前期或不良结局。

关键数值与推荐

  • 血清可溶性fms样酪氨酸激酶1/胎盘生长因子比值 cutoff 为40。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An imbalance of the antiangiogenic factor, soluble fms-like tyrosine kinase-1, and proangiogenic factor, placental growth factor, in the circulation is a reliable predictor for the development of preeclampsia with severe features and related adverse outcomes. In 2023, the US Food and Drug Administration approved a serum soluble fms-like tyrosine kinase-1/placental growth factor test at a cutoff of 40 to aid in the risk assessment of women hospitalized for hypertensive disorders of pregnancy for the progression to preeclampsia with severe features between 23 and 35 weeks. OBJECTIVE: This study aimed to generate real-world evidence for clinical utility for serum soluble fms-like tyrosine kinase-1/placental growth factor test when made available to clinicians in a timely fashion as an aid in risk stratification of development of preeclampsia with severe features within 2 weeks of testing among hospitalized patients with hypertensive disorders of pregnancy. STUDY DESIGN: Hospitalized patients with hypertensive disorders of pregnancy between 23 weeks to 34 weeks and 6 days of gestation were prospectively studied from June 2023 to January 2024 after the implementation of serum soluble fms-like tyrosine kinase-1/placental growth factor testing into routine clinical practice. Serum samples were obtained from patients via venipuncture and analyzed on an automated immunoassay platform (placental growth factor and soluble fms-like tyrosine kinase-1 assays; Thermo Fisher Scientific). Before implementation, physicians were educated on appropriate use and management guidelines on the basis of biomarkers but made pragmatic management decisions independently. Results of soluble fms-like tyrosine kinase-1/placental growth factor tests were available to clinicians within 24 hours of venipuncture. The association between soluble fms-like tyrosine kinase-1/placental growth factor ≥40 and progression to preeclampsia with severe features and adverse maternal/perinatal outcomes were assessed. RESULTS: Of the 65 patient encounters, 36 had a soluble fms-like tyrosine kinase-1/placental growth factor <40 (55.4%). The rate of delivery for indications related to hypertensive disorders of pregnancy within 2 weeks was significantly lower among encounters with a low ratio vs high ratio (2/36 [5.6%] vs 21/29 [72.4%]) even after controlling for relevant confounders (adjusted hazard ratio, 7.52; 95% confidence interval, 3.05-18.54; P<.001). A diagnosis of preeclampsia with severe features within 2 weeks of testing was also less likely among the encounters with soluble fms-like tyrosine kinase-1/placental growth factor ratio <40 when compared with soluble fms-like tyrosine kinase-1/placental growth factor ratio ≥40 (2/36 [5.6%] vs 23/29 [79.3%], P<.001; positive predictive value of 79% [95% confidence interval, 0.65-0.94] and negative predictive value of 0.94 [95% confidence interval, 0.87-1.00]). The positive and negative likelihood ratios for the development of preeclampsia with severe features within 2 weeks of testing were 6.13 and 0.09, respectively. Encounters with a soluble fms-like tyrosine kinase-1/placental growth factor ratio <40 were less likely to experience a maternal or fetal adverse event as compared with encounters with soluble fms-like tyrosine kinase-1/placental growth factor ratio ≥40 (3/36 [8.3%] vs 10/29 [34.5%], P=.01). Among 36 encounters involving low soluble fms-like tyrosine kinase-1/placental growth factor values, 22 had had equivocal clinical or laboratory criteria resembling preeclampsia at presentation but were expectantly managed on the basis of biomarkers, and none developed preeclampsia with severe features or adverse outcomes at 2 weeks. The median latency defined as days between biomarker measurement and delivery in patients with a low biomarker ratio was 33 (interquartile ratio, 23-47) vs 7 (interquartile ratio, 4-14) days among patients with a high ratio (P<.001). Corticosteroid use within 2 weeks was also significantly reduced in the low biomarker group when compared with the high biomarker group (8/35 [22.9%] vs 24/29 [82.8%], P<.001). CONCLUSION: In this study, the incorporation of soluble fms-like tyrosine kinase-1/placental growth factor ratio into clinical practice serves as a dependable supplement in assessing risk for progression to preeclampsia with severe features and adverse outcomes in patients with hypertensive disorders of pregnancy in the United States. Among patients with a low ratio, pregnancy may be prolonged, which results in better neonatal outcomes without harm to the mother.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Burns LP, Potchileev S, Mueller A, et al. Real-world evidence for the utility of serum soluble fms-like tyrosine kinase 1/placental growth factor test for routine clinical evaluation of hospitalized women with hypertensive disorders of pregnancy. Am J Obstet Gynecol. 2024. PMID: 39029547. doi:10.1016/j.ajog.2024.07.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。